Performance of NTLA Intellia Therapeutics | -42.7% in 12m
Compare NTLA with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare Intellia Therapeutics with its related Sector/Index XBI
Performance Duell NTLA vs XBI
| TimeFrame | NTLA | XBI |
|---|---|---|
| 1 Day | 1.90% | 2.02% |
| 1 Week | 14.0% | 3.93% |
| 1 Month | 14.4% | 7.25% |
| 3 Months | -7.90% | -0.71% |
| 6 Months | -1.35% | 30.27% |
| 12 Months | -42.7% | 5.80% |
| YTD | -14.9% | 2.64% |
| Rel. Perf. 1m | 0.70 | |
| Rel. Perf. 3m | -1.99 | |
| Rel. Perf. 6m | -2.58 | |
| Rel. Perf. 12m | -6.03 |
Is Intellia Therapeutics a good stock to buy?
No, based on ValueRay Fundamental Analyses, Intellia Therapeutics (NASDAQ:NTLA) is currently (May 2024)
a stock to sell. It has a ValueRay Fundamental Rating of -80.90 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NTLA as of May 2024 is 22.05. This means that NTLA is currently overvalued and has a potential downside of -15.9% (Sold with Premium).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NTLA as of May 2024 is 22.05. This means that NTLA is currently overvalued and has a potential downside of -15.9% (Sold with Premium).
Is NTLA a buy, sell or hold?
- Strong Buy: 17
- Buy: 6
- Hold: 5
- Sell: 0
- Strong Sell: 0
Values above 0%: NTLA is performing better - Values below 0%: NTLA is underperforming
Compare NTLA with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | 11.57% | 9.38% | -20.01% | -72.83% |
| US NASDAQ 100 | QQQ | 11.08% | 9.33% | -19.25% | -82.22% |
| US Dow Jones Industrial 30 | DIA | 11.75% | 8.47% | -16.41% | -64.64% |
| German DAX 40 | DBXD | 12.02% | 9.91% | -20.80% | -60.82% |
| UK FTSE 100 | ISFU | 11.44% | 6.29% | -18.21% | -56.69% |
| Shanghai Shenzhen CSI 300 | CSI 300 | 13.48% | 10.72% | -2.22% | -31.60% |
| Hongkong Hang Seng | HSI | 8.20% | -3.93% | -2.68% | -32.82% |
| Japan Nikkei 225 | EXX7 | 14.07% | 18.61% | -13.42% | -56.27% |
| India NIFTY 50 | INDA | 13.40% | 12.31% | -17.79% | -68.55% |
| Brasil Bovespa | EWZ | 16.38% | 11.74% | 1.18% | -54.01% |
NTLA Intellia Therapeutics vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | 12.44% | 11.62% | -20.25% | -81.55% |
| Consumer Discretionary | XLY | 13.38% | 11.65% | -8.45% | -64.54% |
| Consumer Staples | XLP | 12.98% | 8.63% | -12.72% | -46.12% |
| Energy | XLE | 13.13% | 15.79% | -14.33% | -65.81% |
| Financial | XLF | 12.02% | 8.58% | -24.00% | -76.20% |
| Health Care | XLV | 11.10% | 8.94% | -16.53% | -55.31% |
| Industrial | XLI | 12.72% | 11.19% | -22.41% | -72.10% |
| Materials | XLB | 12.56% | 11.56% | -17.78% | -61.95% |
| Real Estate | XLRE | 9.25% | 8.28% | -11.04% | -51.33% |
| Technology | XLK | 10.00% | 8.69% | -18.68% | -83.81% |
| Utilities | XLU | 10.78% | 0.38% | -20.82% | -52.77% |
| Aerospace & Defense | XAR | 12.73% | 6.40% | -15.83% | -68.78% |
| Biotech | XBI | 10.07% | 7.15% | -31.62% | -48.50% |
| Homebuilder | XHB | 9.66% | 7.48% | -36.69% | -98.07% |
| Retail | XRT | 8.53% | 5.17% | -23.75% | -70.94% |
Does Intellia Therapeutics outperform its market, is NTLA a Sector Leader?
No, over the last 12 months Intellia Therapeutics (NTLA) made -42.70%, while its related Sector, the SPDR S&P Biotech (XBI) made 5.80%.
Over the last 3 months NTLA made -7.90%, while XBI made -0.71%.
No, over the last 12 months Intellia Therapeutics (NTLA) made -42.70%, while its related Sector, the SPDR S&P Biotech (XBI) made 5.80%.
Over the last 3 months NTLA made -7.90%, while XBI made -0.71%.
| Period | NTLA | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 14.40% | 7.25% | 5.02% |
| 3 Months | -7.90% | -0.71% | 5.86% |
| 12 Months | -42.70% | 5.80% | 30.13% |